Indications for administering palivizumab for RSV prophylaxis
PALIVIZUMAB USE | CRITERIA |
---|---|
Routine | Children younger than 2 years of age with CLD due to prematurity who require ongoing medical therapy (oxygen, steroids, or daily bronchodilator therapy) within the 6 months preceding the RSV season |
Children younger than 2 years of age with hemodynamically significant cyanotic and acyanotic heart disease | |
Infants born at 32 weeks’ gestation or earlier who are 6 months of age or younger (with or without CLD) at the start of the RSV season | |
Children in isolated northern or rural remote communities (eg, children who require air transportation to hospital facilities), born before 36 weeks’ gestation, if they are younger than 6 months of age at the onset of RSV season | |
Discretionary | Full-term Inuit infants younger than 6 months of age at the onset of the RSV season in northern remote communities (eg, children who require air transportation to hospital facilities), regardless of gestational age |
Some patients with severe CLD or congenital heart disease, who require ongoing medical therapy | |
Children with severe immunodeficiency diseases and those with other rare conditions, such as Down syndrome, at high risk of developing severe disease with RSV in the first year of life |
CLD—chronic lung disease, RSV—respiratory syncytial virus.
Data from Samson et al.14